Top Biotech Companies in Las Vegas, NV (12)
Catalent, Inc. is a leading global contract development and manufacturing organization (CDMO) whose mission is to develop, manufacture, and supply products that help people live better and healthier lives. Catalent is dedicated to delivering unparalleled service to pharma, biotech, and consumer health customers, supporting product development, launch, and full life-cycle supply. With time-tested experience in development sciences, delivery technologies, and...
Catalent, Inc.'s Top Stability & Growth Strengths
Strong Market Position & Advantage: Independent analyses consistently place Catalent among the top global CDMOs, with meaningful presence in outsourced finished‑dose approvals and a broad end‑to‑end network. Its scale across oral, sterile, biologics, and cell & gene therapy supports late‑stage and commercial programs globally.
Investor Backing & Capital Strength: Novo Holdings’ completed acquisition provides deep‑capital sponsorship and strategic validation, with U.S./EU clearance reinforcing the platform’s importance. Related transactions around sterile sites highlight the strategic value of capabilities aligned to high‑demand medicines.
Future-Ready Strategy: Private ownership and a refreshed operating model aim to focus investment on biologics, cell & gene therapy, and clinical supply. GLP‑1–linked demand signals and capacity plans into the coming years indicate preparedness for sustained growth.
At Elekta, our outcome-driven and cost-efficient solutions provide lasting clinical difference and are developed through sustainable environmental, social and governance practices. We’ve been working openly and proactively with clinicians and our partners for almost half a century to advance precision radiation therapy and meet continuously evolving patient needs—no matter where they are in the world. To us, it's personal, and...
Elekta's Top Stability & Growth Strengths
Strong Market Position & Advantage: Elekta is a top-tier radiotherapy vendor with category leadership in cranial stereotactic radiosurgery and a notable presence in high-field MR-guided therapy, reinforcing durable competitive standing. Recognition for oncology information systems further supports its positioning in cancer centers.
Innovation-Driven Growth: Recent launches such as Elekta Evo and the Elekta ONE software suite, alongside continued advancement of Unity MR‑Linac workflows, indicate a pipeline that is aiding orders and improving mix. These innovations underpin adaptive and image‑guided therapy strategies across the portfolio.
Resilient & Sustainable Growth: Book‑to‑bill ratios above 1.0 and low single‑digit constant‑currency sales growth point to steady underlying expansion. Improving adjusted margins in recent quarters suggest operational gains despite macro headwinds.
At Varian, a Siemens Healthineers company, we envision a world without fear of cancer. For more than 70 years, we have developed, built and delivered innovative cancer care technologies and solutions for our clinical partners around the globe to help them treat millions of patients each year. With an Intelligent Cancer Care approach, we are harnessing advanced technologies like artificial...
Varian's Top Stability & Growth Strengths
Strong Market Position & Advantage: Industry analyses frequently describe external‑beam radiotherapy as a Varian–Elekta near‑duopoly, with Varian often cited at or near the top. Feedback suggests a large installed base, leading software stack, and a broad global service footprint reinforce this position.
Strong Revenue Growth: Company and trade updates state the Varian segment has posted year‑over‑year revenue growth across multiple recent periods within Siemens Healthineers, alongside positive order momentum and a growing backlog. Feedback suggests recent quarterly trends point to continued demand for systems, software, and services.
Strategic Partnerships: Integration with Siemens Healthineers provides access to imaging, diagnostics, and digital platforms, enabling end‑to‑end oncology workflows and cross‑selling advantages. Feedback suggests this parent‑level backing strengthens global reach and execution in tenders.
With 30+ years of experience, 28+ locations, and 2,000+ clinical studies conducted, Elite Clinical Network (ECN) is a trusted leader in clinical research. Our dedicated network of research sites is built on personalized service, investigator diversity, and rigorous quality processes to ensure excellence in every study. Backed by a professional corporate management team, we partner with top physicians across diverse specialties...
An innovative healthcare venture capital firm. Genetics, pharma and wider biotech. America & Asia HQ. Founded in 2010.
CLS focuses on the extraction and conversion of cannabinoids in the United States.
Since our founding in 2003, NMT has made remarkable progress in bringing to market a comprehensive suite of innovative noninvasive
Markman Biologics has obtained a series of novel patents that pertain to Micro Resurfacing of Reconstructive tissue grafts.
Catalent Inc. (NYSE: CTLT), an S&P 500® company, is the global leader in enabling pharma, biotech, and consumer health partners to optimize product development, launch, and full life-cycle supply for patients around the world. With broad and deep scale and expertise in development sciences, delivery technologies, and multi-modality manufacturing, Catalent is a preferred industry partner for personalized medicines, consumer health...
Bio Adaptives provides natural stem cell therapy solutions to create scientifically valid, research-based natural wellness solutions.
